Darshak Sanghavi
Dados Biográficos
| ID | 7707346 |
|---|---|
| NOME | Darshak Sanghavi |
| PRENOMES | Darshak |
| SOBRENOME | Sanghavi |
| ASSINATURA | SANGHAVI D |
| AFILIAÇÕES | Optum (United States) |
| ORCID | 0000-0003-3713-171X |
| VERIFICADO | Sim |
| TOTAL DE OBRAS | 5 |
| TOTAL DE CITAÇÕES | 0 |
| TOTAL COMO AUTOR | 5 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2008 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2020 |
| ÍNDICE H | 0 |
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder
Importance Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking. Objective To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence. Design, Setting, and Participa…
Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder
BACKGROUND: Relative costs of care among treatment options for opioid use disorder (OUD) are unknown. METHODS: We identified a cohort of 40,885 individuals with a new diagnosis of OUD in a large national de-identified claims database covering commercially insured and Medicare Advantage enrollees. We assigned individuals to 1 of 6 mutually exclusive initial treatment pathways: (1) Inpatient Detox/Rehabilitation Treatment Center; (2) Behavioral Hea…
Rethinking Medicaid Coverage and Payment Policy to Promote High Value Care
Accountable Health Communities — Addressing Social Needs through Medicare and Medicaid
To accelerate the development of a scalable delivery model for addressing upstream determinants of health, the Centers for Medicare and Medicaid Services recently announced a 5-year, $157 million test of a payment model called Accountable Health Communities.
Uncertainties in the Absence of Data
Ethical dilemmas arise when there is insufficient scientific evidence to support a clear clinical decision. When a treatment is nearly perfect in its efficacy and outcome and bears tolerable adverse side-effects-such as surgery for acute appendicitisthere is little left to argue against its implementation in the clinical setting. When data is unavailable or particularly difficult to gather, however, physicians face clinical uncertainty. Questions…
Sem obras proeminentes nesta página.
Uncertainties in the Absence of Data
Ethical dilemmas arise when there is insufficient scientific evidence to support a clear clinical decision. When a treatment is nearly perfect in its efficacy and outcome and bears tolerable adverse side-effects-such as surgery for acute appendicitisthere is little left to argue against its implementation in the clinical setting. When data is unavailable or particularly difficult to gather, however, physicians face clinical uncertainty. Questions…
Accountable Health Communities — Addressing Social Needs through Medicare and Medicaid
To accelerate the development of a scalable delivery model for addressing upstream determinants of health, the Centers for Medicare and Medicaid Services recently announced a 5-year, $157 million test of a payment model called Accountable Health Communities.
Rethinking Medicaid Coverage and Payment Policy to Promote High Value Care
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder
Importance Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking. Objective To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence. Design, Setting, and Participa…
Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder
BACKGROUND: Relative costs of care among treatment options for opioid use disorder (OUD) are unknown. METHODS: We identified a cohort of 40,885 individuals with a new diagnosis of OUD in a large national de-identified claims database covering commercially insured and Medicare Advantage enrollees. We assigned individuals to 1 of 6 mutually exclusive initial treatment pathways: (1) Inpatient Detox/Rehabilitation Treatment Center; (2) Behavioral Hea…
Medicine (5 obras) · Health care (4 obras) · Environmental health (3 obras) · Buprenorphine (2 obras) · Business (2 obras) · Computer Science (2 obras) · Economic growth (2 obras) · Emergency Medicine (2 obras) · Healthcare Policy and Management (2 obras) · HIV, Drug Use, Sexual Risk (2 obras)